Peer-Reviewed: Randomized Controlled Trial in Nigeria Shows Ivermectin Exhibits Positive Clinical Benefit in Mild to Moderate COVID-19

Peer-Reviewed Randomized Controlled Trial in Nigeria Shows Ivermectin Exhibits Positive Clinical Benefit in Mild to Moderate COVID-19

TrialSite recently introduced the Nigerian-based IVERCOVID study.  In an interview with the principal investigator Professor Olufemi Babalola, an ophthalmologist and owner of Rachel Eye Center, he shared that the translational proof of concept (PoC) randomized, double blind placebo dose response study involving three treatment groups and 62 patients produced promising results. Dr. Babalola informed TrialSite that the study would be published soon and sure enough, this just occurred and hence this entry. The British peer-reviewed QJM, An International Journal of Medicine publishes this important small Lagos-based PoC study. Sparked by Vice President Yemi Osinbajo’s interest in stimulating a biomedical research culture in what is both the most populated nation and the largest economy on the African continent, Dr. Babalola with colleagues including Professors Chris Bode and Adesuyi Ajayi and peers concluded that sufficient evidence not only supports investment in broader ivermectin-based research programs but also that a drug well-known to Nigeria should be considered for use in clinical management of COVID-19. The use of this economical and available generic drug should be at least ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee